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LETTER TO THE EDITOR
INFLUENZA VIRUS SURVEILLANCE BY THE INSTITUTO ADOLFO LUTZ,  
INFLUENZA SEASON 2014: ANTIVIRAL RESISTANCE
São Paulo, August 4, 2014
Dear Sir,
Neuraminidase (NA) inhibitors (NAIs) are the only antivirals that 
are effective for prophylaxis and the treatment of seasonal influenza 
A and B infections. There are currently two NAIs approved in most 
countries: oseltamivir (Tamiflu; F. Hoffmann - La Roche) and zanamivir 
(Relenza; GlaxoSmithKline plc.). The development of drug resistance 
is a major drawback for any antiviral therapy, and these specific anti-
influenza drugs are not excluded from this rule. Thus, the proper use of 
NAIs and worldwide monitoring for the presence and spread of drug 
resistant influenza viruses are of the utmost importance. The existence 
of a global surveillance network for influenza, underpinning vaccine 
strain selection, is a valuable asset when seeking to track the emergence 
of antiviral resistance.
The Instituto Adolfo Lutz, São Paulo, SP, Brazil, plays a role 
in national and global influenza surveillance. The objective of the 
present study was to monitor antiviral resistance to assist public 
health authorities with decisions regarding prophylaxis and treatment 
strategies.
Using the real time polymerase chain reaction assay (rRT-PCR), 
influenza viruses of type A, subtype H1N1pdm09 and H3N2, as well 
as type B viruses, were identified and antiviral resistance testing 
was conducted using pyrosequencing2 and Sanger dideoxy sequence 
analysis5.
Prior to the emergence of the pandemic virus in 2009, the 
presence of the oseltamivir resistance-conferring marker, H275Y, was 
identified in seasonal influenza A (H1N1). In 2014, influenza virus 
surveillance identified the same marker, H275Y, in an influenza A 
(H1N1) pdm09 strain isolated from a 20 year-old pregnant woman 
living in Mato Grosso/Cuiabá, the Midwest region of Brazil. The virus 
was collected in March 2014. In addition, two permissive secondary 
NA mutations; V241I and N369K were detected in the virus isolated 
in the Midwest region of Brazil1. These mutations are known to 
negate the impact of the NA H275Y oseltamivir resistance mutation 
on viral replicative fitness. This patient was treated with oseltamivir, 
rocephin, azithromycin and made a full recovery from the respiratory 
disease.
The choice of assay for assessing the susceptibility of the influenza 
virus to NAIs depends on factors pertaining to appropriateness of the 
setting, cost, sustainability, speed in obtaining valid results, reliability 
in terms of predictive values, and accessibility. The high sensitivity 
of genotypic assays allows for testing of clinical specimens, thus 
eliminating the need for virus propagation in cell culture. In addition, 
rapid genotypic testing facilitates more appropriate patient management 
and can significantly advance and assist in large-scale epidemiological 
studies of drug-resistant variants4.
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